DRKS00024175招募中不适用

A prospective observational study to evaluate biomarkers and disease mechanisms in patients with moderate to severe atopic dermatitis with systemic therapy - ImmUniverse AD

Department of Dermatology and AllergyUniversity Hospital Schleswig-Holstein (UKSH)0 个研究点目标入组 300 人开始时间: 2021年2月3日最近更新: 2024年8月19日

试验速览

暂无简介。

•1) Written informed consent from the study participant prior to performing any study-related activities.
•2) Age = 18 years at the time of study entry.
•3) Clinically diagnosed atopic dermatitis.
•4) Initiation of systemic therapy for atopic dermatitis by the treating physician as part of routine care
•5) Study participant agrees and, in the judgment of study personnel, is able to comply with the study protocol for the duration of the study

•1) Study participant is not capable of consenting to study participation or adhering to the study protocol.
•2) Tendency to keloid/hypertrophic scarring and/or known wound healing disorder.
•3) Tattooing and/or skin lesions due to a dermatosis in the puncture area not investigated in this study
•4) Needle phobia
•5) Pregnancy
•6) Liver/biliary tract disease present at the time of the study and judged unstable by the study physician, manifested by ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, persistent jaundice, and/or liver cir-rhosis
•7) Known allergy and/or hypersensitivity to the materials used.
•8) Any reason that, in the opinion of the study physician, may prevent safe participation of the study participant.

发起方

Department of Dermatology and AllergyUniversity Hospital Schleswig-Holstein (UKSH)